Vir Biotechnology names Sung Lee CFO, replacing Howard Horn effective March 27

Vir Biotechnology, Inc.

Sung Lee appointed EVP and CFO effective March 27, 2023; Howard Horn steps down as CFO but remains EVP through April 28.
Base salary $525K, target bonus 45%, sign-on cash bonus $500K payable on 1-year anniversary, relocation expenses up to ~$460K.
Equity awards: option for 133K shares and RSUs for 66.5K shares, each vesting over 4 years.
Lee previously served as CFO at MorphoSys AG and Sangamo; prior roles at Gilead Sciences.
Severance provides 12 months pay/benefits + full equity acceleration within 12 months post-change-in-control; 9 months pay outside CIC.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sung Lee

Executive Vice President and Chief Financial Officer

VIR · Vir Biotechnology, Inc.

Effective: 2023-03-27
Filed: February 16, 2023, 6:59 PM ET

On February 13, 2023, the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) appointed Sung Lee as Executive Vice President and Chief Financial Officer of the Company, effective as of March 27, 2023 (the “Effective Date”).

Role change

Howard Horn

Chief Financial Officer

VIR · Vir Biotechnology, Inc.

Effective: 2023-03-27
Successor: Sung Lee
Filed: February 16, 2023, 6:59 PM ET

Howard Horn will step down as Chief Financial Officer of the Company effective upon Mr. Lee’s appointment on the Effective Date, and will remain with Vir as Executive Vice President until April 28, 2023, to assist with the transition.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sung Lee was appointed as Executive Vice President and Chief Financial Officer at Vir Biotechnology, Inc..

Action: appointed
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

On February 13, 2023, the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) appointed Sung Lee as Executive Vice President and Chief Financial Officer of the Company, effective as of March 27, 2023 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Howard Horn changed role as Chief Financial Officer at Vir Biotechnology, Inc..

Action: step down
Role: Chief Financial Officer

Exact text from the filing

Howard Horn will step down as Chief Financial Officer of the Company effective upon Mr. Lee’s appointment on the Effective Date, and will remain with Vir as Executive Vice President until April 28, 2023, to assist with the transition.

View on SEC.gov

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-040755

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.